Literature DB >> 19262584

Intravenous immunoglobulin for neuromuscular disease: costs, benefits and reimbursement.

John W Griffin, Richard A C Hughes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19262584     DOI: 10.1038/ncpneuro1046

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


× No keyword cloud information.
  3 in total

1.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.

Authors:  I Elovaara; S Apostolski; P van Doorn; N E Gilhus; A Hietaharju; J Honkaniemi; I N van Schaik; N Scolding; P Soelberg Sørensen; B Udd
Journal:  Eur J Neurol       Date:  2008-09       Impact factor: 6.089

2.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

Authors:  Richard A C Hughes; Peter Donofrio; Vera Bril; Marinos C Dalakas; Chunqin Deng; Kim Hanna; Hans-Peter Hartung; Norman Latov; Ingemar S J Merkies; Pieter A van Doorn
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182

3.  Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Paul McCrone; Daniel Chisholm; Martin Knapp; Richard Hughes; Giancarlo Comi; Marinos C Dalakas; Isabel Illa; Costas Kilindireas; Eduardo Nobile-Orazio; Anthony Swan; Peter Van den Bergh; Hugh J Willison
Journal:  Eur J Neurol       Date:  2003-11       Impact factor: 6.089

  3 in total
  1 in total

1.  Neuromuscular disease: IVIg for neuromuscular disease-effective but expensive.

Authors:  Richard A Hughes; Michael P Lunn
Journal:  Nat Rev Neurol       Date:  2012-05-22       Impact factor: 42.937

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.